Active Not Recruiting
PHASE2
INTERVENTIONAL
NCT05905133
A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study is a single-arm, open-label, multi-center clinical study designed to assess the safety and efficacy of CBP-201 in eligible subjects with moderate to severe Atopic Dermatitis.
Detailed Description
The study includes a screening period, a treatment period and a follow-up period. The subjects will receive a subcutaneous injection of CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.
Interventions
Name:
CBP-201
Type:
DRUG
Description:
subcutaneous injection
Primary Outcomes
Measure:
Incidence of treatment-emergent adverse events (TEAEs)
TimeFrame:
From Day 1 study drug first administrated to Week 20
Description:
cases/person-years
Trial Information
NCT ID
NCT05905133
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Connect Biopharm LLC
Last Updated
December 15, 2025